Off Patent
April 2026

Treximet

naproxen sodium and sumatriptan succinate

Azurity Pharmaceuticals Inc

Tablet (oral) · NDA 021926

Last listed protection ended
April 2, 2026

The FDA listed 1 patent for Treximet, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,332,183
    Claims the drug product and a use (U-867)
  2. Ended
    Patent 7,332,183
    Pediatric extension: six more months